It was a pleasure to speak with Dr Siew Eng Choon (Monash University, Malaysia) about the first RCT trial conducted in generalised pustular psoriasis (GPP). Effisayil 1 (NCT03782792) is a Phase 2 trial investigating the anti-IL-36 receptor antibody, spesolimab.
The abstract entitled ‘Design and rationale of Effisayil 1, a Phase II, multicenter, randomized, double-blind, placebo-controlled trial of spesolimab in patients with generalized pustular psoriasis with an acute flare’ was presented at AAD VMX, 23-25 April, 2021.
- What is the rationale for the use of spesolimab in the treatment of patients with a GPP flare? (0:21)
- What are the challenges of testing the efficacy and safety of new therapies in GPP? (2:09)
- How does the design and clinical endpoints of the Effisayil 1 study aim to overcome these challenges? (4:52)
Disclosures: Dr Siew Eng Choon has received honoraria for serving as a consultant, advisory board member, and/or speaker for AbbVie, Boehringer Ingelheim, Janssen, Leo, Eli Lilly, Leo, Novartis, Pfizer, GlaxoSmithKline, UCB, MSD and Wyeth.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Gina Furnival.
Filmed in coverage of the AAD VMX 2021.
Share this Video
Related Videos In Psoriasis
Andy Blauvelt, EADV 2021: Deucravacitinib vs Placebo and Apremilast in Scalp Psoriasis
touchIMMUNOLOGY had the pleasure of speaking with Dr Andy Blauvelt (Oregon Medical Research Center, Portland, OR, USA) about the oral TYK2 inhibitor, deucravacitinib, and how it compared to placebo and apremilast in the treatment of scalp psoriasis. His presentation entitled ‘Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Versus Placebo and Apremilast in Scalp […]
Leon Kircik, AAD VMX 2021: Roflumilast Foam in Scalp and Body Psoriasis
Prof. Leon Kircik (Icahn School of Medicine at Mount Sinai, New York, NY, USA) kindly took the time to speak with us about the results from the recent phase 2b study investigating roflumilast foam in the treatment of scalp and body psoriasis. His abstract entitled ‘Once-daily Roflumilast Foam 0.3% for Scalp and Body Psoriasis: A […]
Kim Papp, AAD VMX 2021: Secukinumab PURE Study
We were delighted to discuss with Dr Kim Papp (Probity Medical Research, Waterloo, ON, Canada) results from the PURE study (NCT02786186), designed to investigate the long-term safety profile of secukinumab in patients with moderate to severe chronic plaque psoriasis. The abstract ‘Secukinumab helps achieving clear/almost clear skin and improve quality of life in psoriasis over […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!